Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
April 19, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -- Data presented in a...
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024 07:00 ET
|
Axsome Therapeutics, Inc.
AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting...
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
April 11, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the American Academy of Neurology
Sania Therapeutics to Present at the American Society of Gene & Cell Therapy Annual Meeting
April 11, 2024 07:00 ET
|
Sania Therapeutics
Sania Therapeutics to Present at the American Society of Gene & Cell Therapy Annual Meeting LONDON, UK & NEW YORK, USA – 11 April 2024, Sania Therapeutics (the “Company”), focused on...
AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLA
April 03, 2024 12:09 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE QUE SANTÉ CANADA A JUGÉ ADMISSIBLE LA DEMANDE DE RÉEXAMEN DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE Paris, 3 avril 2024, 18h AB Science SA...
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
April 03, 2024 12:09 ET
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS GRANTED ELIGIBILITY FOR RECONSIDERATION REQUEST FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS Paris, 3 April, 2024,...
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
March 26, 2024 10:25 ET
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company...
Blackford and Pixyl Partner to Aid Detection and Monitoring of Neurological Diseases
March 14, 2024 04:30 ET
|
Blackford; Pixyl
Blackford and Pixyl Partner to Aid Detection and Monitoring of Neurological Diseases
AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune
March 13, 2024 07:59 ET
|
AB Science
COMMUNIQUÉ DE PRESSE DE NOUVELLES RECHERCHES MONTRENT QUE LE MASITINIB LIMITE LES DOMMAGES NEURONAUX DANS UN MODÈLE DE MALADIE NEURODÉGÉNÉRATIVE D'ORIGINE NEUROIMMUNE C'EST LA PREMIÈRE FOIS QUE LE...
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
March 13, 2024 07:59 ET
|
AB Science
PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM...